Clarity Pharmaceuticals Ltd. has released a press release.
Data on SAR-bisPSMA to be presented at EANM
Earlier from Clarity Pharmaceuticals
- Clarity receives $9.8 million R&D tax incentive refund
- Clarity signs a Commercial Manufacturing Agreement for Cu-64 SAR-bisPSMA with Nucleus RadioPharma
- Clarity signs a Commercial Manufacturing Agreement
- Co-PSMA data published in the European Urology journal